Get the Stockscreener App
277.29
1.89%
-5.35
After Hours:
275.22
-2.07
-0.75%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $277.29, with a volume of 4.37M.
It is down -1.89% in the last 24 hours and down -12.57% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$282.64
Open:
$277.04
24h Volume:
4.37M
Relative Volume:
1.42
Market Cap:
$157.90B
Revenue:
$33.42B
Net Income/Loss:
$4.09B
P/E Ratio:
36.73
EPS:
7.55
Net Cash Flow:
$10.39B
1W Performance:
-1.46%
1M Performance:
-12.57%
6M Performance:
-13.71%
1Y Performance:
+5.01%
1-Day Range:
$268.50
$278.68
1-Week Range:
$268.50
$296.17
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
277.29 | 157.90B | 33.42B | 4.09B | 10.39B | 7.55 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (NASDAQ:AMGN) Given New $319.00 Price Target at UBS Group - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Townsquare Capital LLC - MarketBeat
RE Dickinson Investment Advisors LLC Lowers Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sagespring Wealth Partners LLC Buys Shares of 14,505 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Kennedy Capital Management LLC - MarketBeat
Renaissance Technologies LLC Makes New $18 Million Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Here's Why Amgen (AMGN) is a Strong Value Stock - Yahoo Finance
William Blair Issues Pessimistic Forecast for Amgen Earnings - MarketBeat
Advent Capital Management DE Purchases New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
United Capital Financial Advisors LLC Trims Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Follow the Data - Amgen
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Jaffetilchin Investment Partners LLC - MarketBeat
Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Targeted Therapy Market Future Business Opportunities 2025-2032 | Amgen Inc., GlaxoSmithKline plc, Sanofi - openPR.com
Amgen: The Biotech That Knows How To Make Money (NASDAQ:AMGN) - Seeking Alpha
Integrity Wealth Advisors Inc. Acquires Shares of 3,750 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Rossby Financial LCC Takes $235,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Guggenheim Capital LLC Sells 8,356 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
CreativeOne Wealth LLC Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by LSV Asset Management - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
NVIDIA Corp., Amgen share losses contribute to Dow's 886-point drop - MSN
NVIDIA Corp., Amgen share losses lead Dow's 589-point fall - MSN
Biosimilars Market Set to Witness Significant Growth - openPR.com
NVIDIA Corp., Amgen share losses lead Dow's 200-point fall - MSN
Leqembi finally secures EU clearance; Sandoz sues Amgen over Enbrel patents - BioPharma Dive
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Mariner LLC - MarketBeat
Belpointe Asset Management LLC Purchases 1,638 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Fund Update: FERGUSON WELLMAN CAPITAL MANAGEMENT, INC added 170,577 shares of AMGEN ($AMGN) to their portfolio - Nasdaq
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Trustmark National Bank Trust Department - MarketBeat
Advisors Capital Management LLC Purchases 3,427 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Herceptin Biosimilar Market Overall Study Report 2025-2032 | - openPR.com
Qtron Investments LLC Lowers Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Philadelphia Trust Co. Reduces Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bessemer Group Inc. Has $10.49 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Alston & Bird Allege Big Pharma Company Amgen Monopolized US Arthritis Drug Market - Law.com
HHS Rejects Amgen, Lilly Fight of Clinics in Drug Discount Plan - Bloomberg Law News
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408, Maintains Buy Rating - marketscreener.com
Lobbying Update: $60,000 of AMGEN INC lobbying was just disclosed - Nasdaq
Savvy Advisors Inc. Buys 2,087 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bragg Financial Advisors Inc Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Stamos Capital Partners L.P. Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
EPO and UPC disagree on validity of Amgen’s patent for cholesterol drug - JUVE Patent
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Legacy Financial Advisors Inc. - MarketBeat
Zuckerman Investment Group LLC Invests $521,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Argent Trust Co Lowers Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Azimuth Capital Investment Management LLC Cuts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Clinical Trial Optimization - Amgen
Human & Disease Biology - Amgen
AI in Research & Development - Amgen
Novel Targets & Modalities - Amgen
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):